Another 6-month, randomized, controlled trial in RA patients with an inadequate response to anti-TNF therapy demonstrated superior efficacy with abatacept, a T-cell costimulatory inhibitor, against placebo [28]. This evidence concerns the gene TNF and rheumatoid arthritis.